Genome wide expression analysis of radiation-induced DNA damage responses in isogenic HCT116 p53+/+ and HCT116 p53−/− colorectal carcinoma cell lines

References

• Acosta JC, Gil J. 2012. Senescence: A new weapon for cancer therapy. Trends Cell Biol 22:211219.
   Web of Science ®Google Scholar
• Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y, Melamed J, D'adda Di Fagagna F, Bernard D, Hernando E, Gil J. 2008. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133:1006–1018.
   PubMed Web of Science ®Google Scholar
• Agarwal ML, Agarwal A, Taylor WR, Stark GR. 1995. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92:8493–8497.
   PubMed Web of Science ®Google Scholar
• Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J. 2003. Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J 22:4212–4222.
   PubMed Web of Science ®Google Scholar
• Bhonde MR, Hanski ML, Budczies J, Cao M, Gillissen B, Moorthy D, Simonetta F, Scherubl H, Truss M, Hagemeier C, Mewes HW, Daniel PT, Zeitz M, Hanski C. 2006. DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: The lack of this suppression in p53MUT cells contributes to apoptosis. J Biol Chem 281:8675–8685.
   PubMed Web of Science ®Google Scholar
• Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JH, Shapiro GI. 2010. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol 21:884–894.
   PubMed Web of Science ®Google Scholar
• Braig M, Schmitt CA. 2006. Oncogene-induced senescence: Putting the brakes on tumor development. Cancer Res 66:2881–2884.
   PubMed Web of Science ®Google Scholar
• Brown JM, Wouters BG. 1999. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391–1399.
   PubMed Web of Science ®Google Scholar
• Burgess A, Vigneron S, Brioudes E, Labbé J-C, Lorca T, Castro A. 2010. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci USA 107:12564–12569.
   PubMed Web of Science ®Google Scholar
• Campisi J. 2011. Cellular senescence: Putting the paradoxes in perspective. Curr Opin Genet Dev 21:107–112.
   PubMed Web of Science ®Google Scholar
• Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC, Roninson IB. 2000. p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene 19:2165–2170.
   PubMed Web of Science ®Google Scholar
• Cho JH, Saini DK, Karunarathne WK, Kalyanaraman V, Gautam N. 2011. Alteration of Golgi structure in senescent cells and its regulation by a G protein gamma subunit. Cell Signal 23:785–793.
   PubMed Web of Science ®Google Scholar
• Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. 2008. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6:2853–2868.
   PubMed Web of Science ®Google Scholar
• Davis TA, Landauer MR, Mog SR, Barshishat-Kupper M, Zins SR, Amare MF, Day RM. 2010. Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation. Exp Hematol 38:270–281.
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. 2009. Rapamycin decelerates cellular senescence. Cell Cycle 8:1888–1895.
   PubMed Web of Science ®Google Scholar
• Eckerdt F, Yuan J, Strebhardt K. 2005. Polo-like kinases and oncogenesis. Oncogene 24:267–276.
   PubMed Web of Science ®Google Scholar
• Eriksson D, Blomberg J, Lindgren T, Lofroth PO, Johansson L, Riklund K, Stigbrand T. 2008. Iodine-131 induces mitotic catastrophes and activates apoptotic pathways in HeLa Hep2 cells. Cancer Biother Radiopharm 23:541–549.
   PubMed Web of Science ®Google Scholar
• Eriksson D, Lofroth PO, Johansson L, Riklund KA, Stigbrand T. 2007. Cell cycle disturbances and mitotic catastrophes in HeLa Hep2 cells following 2.5 to 10 Gy of ionizing radiation. Clin Cancer Res 13:5501s–5508s.
   PubMed Web of Science ®Google Scholar
• Eriksson D, Stigbrand T. 2010. Radiation-induced cell death mechanisms. Tumour Biol 31:363–372.
   PubMed Web of Science ®Google Scholar
• Fei P, El-Deiry WS. 2003. P53 and radiation responses. Oncogene 22:5774–5783.
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Ohlsson R, Henikoff S. 2006. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33.
   PubMed Web of Science ®Google Scholar
• Ferrandiz N, Caraballo JM, Garcia-Gutierrez L, Devgan V, Rodriguez-Paredes M, Lafita MC, Bretones G, Quintanilla A, Munoz-Alonso MJ, Blanco R, Reyes JC, Agell N, Delgado MD, Dotto GP, Leon J. 2012. p21 as a transcriptional co-repressor of S-phase and mitotic control genes. PLoS One 7:25.
   Web of Science ®Google Scholar
• Fletcher L, Cerniglia GJ, Nigg EA, Yen TJ, Muschel RJ. 2004. Inhibition of centrosome separation after DNA damage: A role for Nek2. Radiat Res 162:128–135.
   PubMed Web of Science ®Google Scholar
• Freund A, Laberge RM, Demaria M, Campisi J. 2012. Lamin B1 loss is a senescence-associated biomarker. Mol Biol Cell 23:2066–2075.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. 2007. Cell death modalities: Classification and pathophysiological implications. Cell Death Differ 14:1237–1243.
   PubMed Web of Science ®Google Scholar
• Gojo I, Perl A, Luger S, Baer MR, Norsworthy KJ, Bauer KS, Tidwell M, Fleckinger S, Carroll M, Sausville EA. 2013. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs 27:27.
   Google Scholar
• Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brummendorf TH. 2008. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111: 4355–4364.
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49–53.
   PubMed Web of Science ®Google Scholar
• Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, Chang MS. 2012. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol 188:1981–1991.
   PubMed Web of Science ®Google Scholar
• Hwang ES, Yoon G, Kang HT. 2009. A comparative analysis of the cell biology of senescence and aging. Cell Mol Life Sci 66:2503–2524.
   PubMed Web of Science ®Google Scholar
• Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jacobs JJ, Van Lohuizen M, Band V, Campisi J, Dimri GP. 2003. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 23:389–401.
   PubMed Web of Science ®Google Scholar
• Kimura S. 2010. AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 11:1442–1449.
   PubMedGoogle Scholar
• Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE. 2004. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114:1299–1307.
   PubMed Web of Science ®Google Scholar
• Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. 2010. The essence of senescence. Genes Dev 24:2463–2479.
   PubMed Web of Science ®Google Scholar
• Kuilman T, Michaloglou C, Vredeveld LC, Douma S, Van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. 2008. Oncogene- induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133:1019–1031.
   PubMed Web of Science ®Google Scholar
• Kuilman T, Peeper DS. 2009. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 9:81–94.
   PubMed Web of Science ®Google Scholar
• Kwon OH, Park JL, Kim M, Kim JH, Lee HC, Kim HJ, Noh SM, Song KS, Yoo HS, Paik SG, Kim SY, Kim YS. 2011. Aberrant up-regulation of LAMB3 and LAMC2 by promoter demethylation in gastric cancer. Biochem Biophys Res Commun 406:539–545.
   PubMed Web of Science ®Google Scholar
• Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. 2005. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7:126–136.
   PubMed Web of Science ®Google Scholar
• Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, Wagner L, Ho AD, Salisbury JL, Boutros M, Krämer A. 2010. Proteins required for centrosome clustering in cancer cells. Sci Translat Med 2:33ra38.
   PubMed Web of Science ®Google Scholar
• Loffler H, Lukas J, Bartek J, Kramer A. 2006. Structure meets function – centrosomes, genome maintenance and the DNA damage response. Exp Cell Res 312:2633–2640.
   PubMed Web of Science ®Google Scholar
• Lu KP, Zhou XZ. 2007. The prolyl isomerase PIN1: A pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8:904–916.
   PubMed Web of Science ®Google Scholar
• Lu L-Y, Wood JL, Ye L, Minter-Dykhouse K, Saunders TL, Yu X, Chen J. 2008. Aurora A is essential for early embryonic development and tumor suppression. J Biolog Chem 283:31785–31790.
   PubMed Web of Science ®Google Scholar
• Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM. 2013. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 137:483–492.
   PubMed Web of Science ®Google Scholar
• Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. 2012. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res 18:2048–2055.
   PubMed Web of Science ®Google Scholar
• Mirzayans R, Andrais B, Scott A, Murray D. 2012. New insights into p53 signaling and cancer cell response to DNS damage: Implications for cancer therapy. J Biomed Biotechnol 2012:170325.
   PubMedGoogle Scholar
• Muller PA, Vousden KH, Norman JC. 2011. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192:209–218.
   PubMed Web of Science ®Google Scholar
• Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G, Keen N, Schwartz GK. 2009. Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell 20: 2218–2228.
   Google Scholar
• Nam H-J, Chae S, Jang S-H, Cho H, Lee J-H. 2010. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis 31:1531–1540.
   PubMed Web of Science ®Google Scholar
• Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T, Ushio Y, Saya H. 2004. Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene 23:6548–6558.
   PubMedGoogle Scholar
• Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, De Bono JS, Blagden SP. 2011. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 17:3420–3430.
   PubMed Web of Science ®Google Scholar
• Perez De Castro I, De Carcer G, Malumbres M. 2007. A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis 28:899–912.
   PubMed Web of Science ®Google Scholar
• Petersen L, Hasvold G, Lukas J, Bartek J, Syljuasen RG. 2010. p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors. Cell Prolif 43:365–371.
   PubMed Web of Science ®Google Scholar
• Radford IR, Murphy TK, Radley JM, Ellis SL. 1994. Radiation response of mouse lymphoid and myeloid cell lines. Part II. Apoptotic death is shown by all lines examined. Int J Radiat Biol 65:217–227.
   PubMed Web of Science ®Google Scholar
• Rodier F, Campisi J. 2011. Four faces of cellular senescence. J Cell Biol 192:547–556.
   PubMed Web of Science ®Google Scholar
• Roninson IB, Broude EV, Chang BD. 2001. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4:303–313.
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–1108.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI. 2013. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 31:370–380.
   PubMed Web of Science ®Google Scholar
• Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R, Giorgini ML, Cappella P, Ballinari D, Sola F, Varasi M, Bravo R, Moll J. 2006. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 12:4080–4089.
   PubMed Web of Science ®Google Scholar
• Soussi T, Beroud C. 2001. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233–240.
   PubMed Web of Science ®Google Scholar
• Soussi T, Lozano G. 2005. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331:834–842.
   PubMed Web of Science ®Google Scholar
• Stewart S, Fang G. 2005. Anaphase-promoting complex/cyclosome controls the stability of TPX2 during mitotic exit. Mol Cell Biol 25:10516–10527.
   PubMed Web of Science ®Google Scholar
• Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N. 2009. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106:3964–3949.
   PubMed Web of Science ®Google Scholar
• Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, Scorilas A, Xynopoulos D, Diamandis EP. 2009. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer 100:1659–1665.
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR. 2001. Regulation of the G2/M transition by p53. Oncogene 20:1803–1815.
   PubMed Web of Science ®Google Scholar
• Tchkonia T, Zhu Y, Van Deursen J, Campisi J, Kirkland JL. 2013. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest 123:966–972.
   PubMed Web of Science ®Google Scholar
• Tian H, Faje AT, Lee SL, Jorgensen TJ. 2002. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. Neoplasia 4:171–180.
   Google Scholar
• Walsby E, Walsh V, Pepper C, Burnett A, Mills K. 2008. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 93: 662–669.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lu X. 2002. Live or let die: The cell's response to p53. Nat Rev Cancer 2:594–604.
   PubMed Web of Science ®Google Scholar
• Wouters BG, Giaccia AJ, Denko NC, Brown JM. 1997. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 57:4703–4706.
   PubMed Web of Science ®Google Scholar
• Wu G, Xu L, Lin N, Liu B. 2013. UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines. BMC Cancer 13:1471–2407.
   Web of Science ®Google Scholar